---
figid: PMC4655250__WJEM-5-206-g002
figlink: /pmc/articles/PMC4655250/figure/F2/
number: Figure 2
caption: 'Proposed models for the mechanistic role of endoplasmic reticulum stress
  in the modulation of the anti-tumor efficiency of vemurafenib, dabrafenib and trametenib
  in melanoma patients harboring activating neuroblastoma RAS viral (v-ras) oncogene
  homolog or rapidly accelerated fibrosarcoma murine sarcoma viral (v-raf) oncogene
  homolog B mutations. The main function of MC1R, TRK on melanoma cell is to transmit
  extracellular signaling that is essential for the activation of RAS-RAF-MEK-ERK
  and PI3K-AKT-mTOR pathways to mediate various cellular functions including melanoma
  initiation, progression and resistance. Thus, the exposure of melanoma (BRAFmt and
  NRASmt) cells to either Vemurafenib, Dabrafenib or Trametenib, respectively, results
  in inhibition of MC1R, cKIT and TRK-mediated activation of RAS-RAF-MEK-ERK and PI3K-AKT-mTOR
  pathways. As consequence the inhibition of RAS-RAF-MEK-ERK and PI3K-AKT-mTOR pathways
  results in the execution melanoma cell death via mechanism-mediated by ER stress-dependent
  pathways including PERK-eIF2α-ATF4-ATF3-CHOP-Bim pathway. NRAS: Neuroblastoma Rat
  Sarcoma viral (v-ras) oncogene homolog; BRAF: Rapidly Accelerated Fibrosarcoma murine
  sarcoma viral (v-raf) oncogene homolog B; MC1R: Melanocortin 1 receptor; TRK: CKIT
  and receptor tyrosine kinase; PI3K: Phosphatidylinositol-4,5-bisphosphate 3-kinase;
  AKT: Protein kinase B.'
pmcid: PMC4655250
papertitle: 'Endoplasmic reticulum stress-mediated pathways to both apoptosis and
  autophagy: Significance for melanoma treatment.'
reftext: Mohamed Hassan, et al. World J Exp Med. 2015 Nov 20;5(4):206-217.
pmc_ranked_result_index: '158147'
pathway_score: 0.9606004
filename: WJEM-5-206-g002.jpg
figtitle: 'Endoplasmic reticulum stress-mediated pathways to both apoptosis and autophagy:
  Significance for melanoma treatment.'
year: '2015'
organisms: Homo sapiens
ndex: 5de37e18-dedd-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC4655250__WJEM-5-206-g002.html
  '@type': Dataset
  description: 'Proposed models for the mechanistic role of endoplasmic reticulum
    stress in the modulation of the anti-tumor efficiency of vemurafenib, dabrafenib
    and trametenib in melanoma patients harboring activating neuroblastoma RAS viral
    (v-ras) oncogene homolog or rapidly accelerated fibrosarcoma murine sarcoma viral
    (v-raf) oncogene homolog B mutations. The main function of MC1R, TRK on melanoma
    cell is to transmit extracellular signaling that is essential for the activation
    of RAS-RAF-MEK-ERK and PI3K-AKT-mTOR pathways to mediate various cellular functions
    including melanoma initiation, progression and resistance. Thus, the exposure
    of melanoma (BRAFmt and NRASmt) cells to either Vemurafenib, Dabrafenib or Trametenib,
    respectively, results in inhibition of MC1R, cKIT and TRK-mediated activation
    of RAS-RAF-MEK-ERK and PI3K-AKT-mTOR pathways. As consequence the inhibition of
    RAS-RAF-MEK-ERK and PI3K-AKT-mTOR pathways results in the execution melanoma cell
    death via mechanism-mediated by ER stress-dependent pathways including PERK-eIF2α-ATF4-ATF3-CHOP-Bim
    pathway. NRAS: Neuroblastoma Rat Sarcoma viral (v-ras) oncogene homolog; BRAF:
    Rapidly Accelerated Fibrosarcoma murine sarcoma viral (v-raf) oncogene homolog
    B; MC1R: Melanocortin 1 receptor; TRK: CKIT and receptor tyrosine kinase; PI3K:
    Phosphatidylinositol-4,5-bisphosphate 3-kinase; AKT: Protein kinase B.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - BRAF
  - AKT1
  - AKT2
  - AKT3
  - BCL2L11
  - PTEN
  - KIT
  - MITF
  - MTOR
  - MC1R
  - HSPA5
  - ATF3
  - ATF4
  - EIF2AK3
  - GNAL
  - DDIT3
  - MAP2K1
  - GNAS
  - MAP2K2
  - Trametinib
  - Dabrafenib
  - Cancer
genes:
- word: BRAF
  symbol: BRAF
  source: hgnc_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: Bim
  symbol: BIM
  source: hgnc_alias_symbol
  hgnc_symbol: BCL2L11
  entrez: '10018'
- word: PTEN
  symbol: PTEN
  source: hgnc_symbol
  hgnc_symbol: PTEN
  entrez: '5728'
- word: CKIT
  symbol: C-Kit
  source: hgnc_alias_symbol
  hgnc_symbol: KIT
  entrez: '3815'
- word: (MITF
  symbol: MITF
  source: hgnc_symbol
  hgnc_symbol: MITF
  entrez: '4286'
- word: MTOR
  symbol: MTOR
  source: hgnc_symbol
  hgnc_symbol: MTOR
  entrez: '2475'
- word: MC1R
  symbol: MC1R
  source: hgnc_symbol
  hgnc_symbol: MC1R
  entrez: '4157'
- word: GRP78
  symbol: GRP78
  source: hgnc_prev_symbol
  hgnc_symbol: HSPA5
  entrez: '3309'
- word: ATF3
  symbol: ATF3
  source: hgnc_symbol
  hgnc_symbol: ATF3
  entrez: '467'
- word: ATF4
  symbol: ATF4
  source: hgnc_symbol
  hgnc_symbol: ATF4
  entrez: '468'
- word: PERK
  symbol: PERK
  source: hgnc_alias_symbol
  hgnc_symbol: EIF2AK3
  entrez: '9451'
- word: G1/S
  symbol: Gs
  source: bioentities_symbol
  hgnc_symbol: GNAL
  entrez: '2774'
- word: CHOP)
  symbol: CHOP
  source: hgnc_alias_symbol
  hgnc_symbol: DDIT3
  entrez: '1649'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
- word: G1/S
  symbol: Gs
  source: bioentities_symbol
  hgnc_symbol: GNAS
  entrez: '2778'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
chemicals:
- word: Trametinib
  source: MESH
  identifier: C560077
- word: Dabrafenib
  source: MESH
  identifier: C561627
diseases:
- word: Cancer
  source: ''
  identifier: ''
---
